ADC Antibody Development
Based on “Integrated and Innovative Antibody-drug Conjugates R&D Platform” and “Super Trillion Antibody Library Platform”, we can customize the screening of the best antibody suitable for ADC drug development for partners, and can also provide overall R&D services for ADC drugs from target to Pre-clinical candidates.
Service Highlights
1. Integrated platform for innovative ADC discovery
10 functional modules and 40+ sub-platforms cover the whole antibody discovery process.
Professional project management system, seamless integration among all modules, and high efficiency for PCC completion (12 months).
2. Unique multi-pathway antibody generation platform
Seven trillion large-capacity antibody library, thousands of lead molecules for conventional targets can be obtained.
Diverse antibody sources: natural B-cell antibodies, B-cell rearranged antibodies, synthetic and semi-synthetic antibodies, mouse immunization library, alpaca immunization library.
Full coverage of molecular formats: full antibodies, single domain antibodies, bispecific antibodies, mouse monoclonal antibodies, rat monoclonal antibodies.
3. Rapid & high-throughput conjugation platform
High-throughput, stable and controlled conjugation platform for efficient screening of lead antibodies.
Multiple conjugation methods evaluation: flexible combination of payloads and linkers.
4. Experienced & professional research team
20+ scientists in various fields, systematic and scientific project development.
100+ projects development experience, high rate for successful project deliver.
5. Flexible customization services
Customized innovative ADC R&D with diversified service forms.
Flexible combination of ADC three core elements to suit different R&D needs.
Popular articles
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreAfter the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.
Learn more